search
Back to results

Proof of Mechanism in ELT (PoM)

Primary Purpose

Premature Ejaculation

Status
Completed
Phase
Phase 1
Locations
Italy
Study Type
Interventional
Intervention
GSK958108
Placebo
Sponsored by
GlaxoSmithKline
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Premature Ejaculation

Eligibility Criteria

18 Years - 50 Years (Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Heterosexual male subject with self-reported moderate or severe primary Premature ejaculation with ejaculation occurring on or before penetration, or shortly there after with minimal stimulation
  • Baseline Ejaculation Latency time < 3 minutes
  • Subjects must agree to use a contraception methods as per protocol
  • Body weight > or = 50 kg and Body Mass Index within the range 19.0-29.9 Kg/m2
  • Subject with normal visual acuity (with appropriate correction if needed)
  • Subject able to cooperate in all study procedure including the eye examination with use of mydriatics

Exclusion Criteria:

  • Erectile dysfunction
  • History of migraine
  • Current clinically relevant abnormality
  • History of psychiatric illness or suicidal attempts or behaviours
  • History of any eye disorder or colour blind, excluding myopia and presbyopia
  • Cardiac conduction disorder or other clinically significant cardiac disease
  • Positive at pre-study drug/alcohol screen and to Hepatitis or HIV tests
  • Regular consumption of alcohol
  • History of sensitivity or intolerance to drugs
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice [and/or pummelos, exotic citrus fruits, grapefruit hybrids] from 7 days prior to the first dose of study medication
  • Subject has received or is continuing to receive any treatment for premature ejaculation in the four weeks prior to the study start
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements prior to the first dose of study medication
  • Participation in another clinical trial in the previous month
  • Exposure to more than four new experimental drugs within the previous 12 months
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Unwillingness or inability to follow the procedures outlined in the protocol.

Sites / Locations

  • GSK Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

GSK958108 3 mg

Placebo of GSK958108

Arm Description

Experimental

Placebo

Outcomes

Primary Outcome Measures

Time to achieve ejaculation from the start of masturbation during audio-video erotic stimuli

Secondary Outcome Measures

Safety and tolerability measured as adverse events occurrence, vital signs variations, safety laboratory, eye assessments, ECG and physical examination
Blood concentration of GSK958108 at different timepoints

Full Information

First Posted
March 12, 2009
Last Updated
June 13, 2017
Sponsor
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT00861484
Brief Title
Proof of Mechanism in ELT
Acronym
PoM
Official Title
A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
November 26, 2008 (Actual)
Primary Completion Date
December 11, 2009 (Actual)
Study Completion Date
December 11, 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine if the administration of GSK958108 can delay ejaculation in patients with primary premature ejaculation as measured by the ejaculatory latency time (ELT) using the masturbation model and sexual visual stimulation, and to evaluate the safety and tolerability of GSK958108 in healthy men with PE

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Ejaculation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
33 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GSK958108 3 mg
Arm Type
Experimental
Arm Description
Experimental
Arm Title
Placebo of GSK958108
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
GSK958108
Intervention Description
Coated Tablets 1 mg
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Coated tablets
Primary Outcome Measure Information:
Title
Time to achieve ejaculation from the start of masturbation during audio-video erotic stimuli
Time Frame
50 minutes
Secondary Outcome Measure Information:
Title
Safety and tolerability measured as adverse events occurrence, vital signs variations, safety laboratory, eye assessments, ECG and physical examination
Time Frame
8 weeks
Title
Blood concentration of GSK958108 at different timepoints
Time Frame
From predose to 30 hours post-dose

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Heterosexual male subject with self-reported moderate or severe primary Premature ejaculation with ejaculation occurring on or before penetration, or shortly there after with minimal stimulation Baseline Ejaculation Latency time < 3 minutes Subjects must agree to use a contraception methods as per protocol Body weight > or = 50 kg and Body Mass Index within the range 19.0-29.9 Kg/m2 Subject with normal visual acuity (with appropriate correction if needed) Subject able to cooperate in all study procedure including the eye examination with use of mydriatics Exclusion Criteria: Erectile dysfunction History of migraine Current clinically relevant abnormality History of psychiatric illness or suicidal attempts or behaviours History of any eye disorder or colour blind, excluding myopia and presbyopia Cardiac conduction disorder or other clinically significant cardiac disease Positive at pre-study drug/alcohol screen and to Hepatitis or HIV tests Regular consumption of alcohol History of sensitivity or intolerance to drugs Consumption of red wine, seville oranges, grapefruit or grapefruit juice [and/or pummelos, exotic citrus fruits, grapefruit hybrids] from 7 days prior to the first dose of study medication Subject has received or is continuing to receive any treatment for premature ejaculation in the four weeks prior to the study start Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements prior to the first dose of study medication Participation in another clinical trial in the previous month Exposure to more than four new experimental drugs within the previous 12 months Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. Unwillingness or inability to follow the procedures outlined in the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Verona
State/Province
Veneto
ZIP/Postal Code
37134
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Links:
URL
https://www.clinicalstudydatarequest.com
Description
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Available IPD and Supporting Information:
Available IPD/Information Type
Study Protocol
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Dataset Specification
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Informed Consent Form
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Statistical Analysis Plan
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Individual Participant Data Set
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Annotated Case Report Form
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Clinical Study Report
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register

Learn more about this trial

Proof of Mechanism in ELT

We'll reach out to this number within 24 hrs